WallStreetZenWallStreetZen

NASDAQ: DCPH
Deciphera Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

DCPH past revenue growth

How has DCPH's revenue growth performed historically?
Company
21.87%
Industry
10.14%
Market
17.55%
DCPH's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
DCPH's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
DCPH's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

DCPH earnings and revenue history

Current Revenue
$163.4M
Current Earnings
-$194.9M
Current Profit Margin
-119.3%

DCPH Return on Equity

Current Company
-49.4%
Current Industry
15.4%
Current Market
188%
DCPH's Return on Equity (-49.4%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when DCPH announces earnings.

DCPH Return on Assets

Current Company
-38.4%
Current Industry
3.4%
DCPH is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

DCPH Return on Capital Employed

Current Company
-52.11%
Current Industry
5.1%
DCPH's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

DCPH vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
DCPH$163.36M-$187.94M-$194.94M+59.88%N/A
COLL$566.77M$308.33M$48.16M+15.11%+94.10%
IRWD$442.74M-$895.55M-$1.00B+5.02%N/A
PCRX$674.98M$157.58M$41.96M+14.88%-90.17%
ANIP$486.82M$107.87M$17.15M+19.28%-8.07%
View Top Pharmaceutical Stocks

DCPH earnings dates

Next earnings date
Jun 20, 2024

Deciphera Pharmaceuticals Earnings & Revenue FAQ

What were DCPH's earnings last quarter?

On Invalid Date, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 2023 earnings per share (EPS) of -$0.54, up 1.82% year over year. Total Deciphera Pharmaceuticals earnings for the quarter were -$47.19 million. In the same quarter last year, Deciphera Pharmaceuticals's earnings per share (EPS) was -$0.55.

If you're new to stock investing, here's how to buy Deciphera Pharmaceuticals stock.

What was DCPH's earnings growth in the past year?

As of Q2 2024, Deciphera Pharmaceuticals's earnings has grown year over year. Deciphera Pharmaceuticals's earnings in the past year totalled -$194.94 million.

What is DCPH's earnings date?

Deciphera Pharmaceuticals's earnings date is Invalid Date. Add DCPH to your watchlist to be reminded of DCPH's next earnings announcement.

What was DCPH's revenue last quarter?

On Invalid Date, Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q4 2023 revenue of $48.29 million up 32.88% year over year. In the same quarter last year, Deciphera Pharmaceuticals's revenue was $36.35 million.

What was DCPH's revenue growth in the past year?

As of Q2 2024, Deciphera Pharmaceuticals's revenue has grown 21.87% year over year. This is 11.74 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 10.14%. Deciphera Pharmaceuticals's revenue in the past year totalled $163.36 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.